Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALS-L1023
- Development stage
- Phase 2
- Lead developer
- AngioLab
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALS-L1023 is an oral angiogenesis inhibitor derived from the ethyl acetate extract of *Melissa officinalis* L. (lemon balm) leaves. It is being developed primarily for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and wet age-related macular degeneration (AMD). The drug acts by inhibiting angiogenic factors such as vascular endothelial growth factor A (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and matrix metalloproteinases (MMPs). Preclinical and clinical studies suggest that ALS-L1023 reduces hepatic fat content, alleviates liver fibrosis, and may improve visual outcomes in AMD by protecting retinal pigment epithelial cells from oxidative stress-induced apoptosis. The drug has shown a favorable safety profile in clinical trials[1][2][5][6].
- Brand names
- AL101-MASHAL-101-MASHAL 101-MASH
- Other names
- Melissa leaf ethyl acetate dried extractlemon balm extract (ALS-L1023)
02
Targets
MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)MMP12 (Macrophage Metalloelastase)PDGFR (PDGFR family)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ALS-L1023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALS-L1023.